Gastroenterology
PMCID: PMC12175440 PMID: 40533762 DOI: 10.1186/s12957-025-03823-0 Journal: World journal of surgical oncology Publication Date: 2025-6-18 Authors: Wood PC, Zammit AP, Ferris B, Simpson FH, Burge M, et al. Key Points * Overall recurrence rate of 13.3% in early-stage CRC, with stage II patients at higher risk * Venous invasion,
Pulmonology
PMCID: PMC12178108 PMID: 40536274 DOI: 10.1111/myc.70083 Journal: Mycoses Publication Date: 2025-6-19 Authors: Tanaka Y, Ide S, Takazono T, Takeda K, Iwanaga N, et al. Key Points * CPA coinfection occurs in 3.5% of NTM-PD patients, with Aspergillus fumigatus being the most common causative species * Male sex, COPD,
Oncology
PMCID: PMC12177888 PMID: 40392078 DOI: 10.1530/ERC-25-0052 Journal: Endocrine-related cancer Publication Date: 2025-6-18 Authors: Siebenhüner AR, Refardt J, Nicolas GP, Kaderli R, Walter MA, et al. Key Points * MKIs represent a significant advancement in GEP-NET treatment, offering improved progression-free survival across multiple tumor subtypes * Median PFS improvements range from
Surgery
PMCID: PMC12176940 PMID: 40533608 DOI: 10.1007/s11701-025-02373-7 Journal: Journal of robotic surgery Publication Date: 2025-6-18 Authors: Özkan E, Çankaya A, Özsoy H Key Points * Nursing students showed varying levels of surgical technology knowledge, with mean knowledge scores of 5.26 for open surgery, 2.49 for laparoscopic surgery, and
Oncology
PMCID: PMC12177246 PMID: 40530452 DOI: 10.1177/19160216251348424 Journal: Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale Publication Date: 2025-6-18 Authors: Patel D, Taylor V, MacKay C, den Besten C, Rigby MH, et al. Key Points * TLM demonstrates comparable oncological outcomes
Oncology
PMCID: PMC12178961 PMID: 40536732 DOI: 10.1007/s00432-025-06246-2 Journal: Journal of cancer research and clinical oncology Publication Date: 2025-6-19 Authors: Schneeweiss A, Fasching PA, Thill M, van Mackelenbergh M, Marme F, et al. Key Points * Nab-paclitaxel demonstrated consistent efficacy across multiple treatment lines in advanced breast cancer * Median progression-free survival
Oncology
PMCID: PMC12176694 PMID: 40534096 DOI: 10.1111/jcmm.70661 Journal: Journal of cellular and molecular medicine Publication Date: 2025-6-18 Authors: Zhu X, Zhang Y, Yu A, Xiao X Key Points * Myeloid cell-derived LGALS9 and epithelial cell P4HB interaction is a previously uncharacterized mechanism driving gastric cancer metastasis * Pharmacological P4HB inhibitors
Infectious_Disease
PMCID: PMC12176104 PMID: 40531694 DOI: 10.15585/mmwr.mm7422a1 Journal: MMWR. Morbidity and mortality weekly report Publication Date: 2025-6-19 Authors: Ortiz N, Rodriguez LR, McPherson M, Pringle K, Rao AK, et al. Key Points * Eight mpox cases identified across four cruise ship voyages, with transmission primarily among crew members and
Psychiatry
PMCID: PMC12176229 PMID: 40531814 DOI: 10.1371/journal.pone.0322923 Journal: PloS one Publication Date: 2025-6-18 Authors: Vakili Sadeghi M, Tehrani MA, Pasha H, Hamidia A, Nabipour M, et al. Key Points * Spiritual well-being significantly and negatively predicts anxiety (β = -0.154, P < 0.001) and depression (β = -0.
Pharmacology
PMCID: PMC12176123 PMID: 40531973 DOI: 10.1371/journal.pone.0325561 Journal: PloS one Publication Date: 2025-6-18 Authors: Munroe ES, Grandits GA, Hyzy RC, Prescott HC, Barrett TW, et al. Key Points * nMAb treatment did not compromise the body's natural immune response in hospitalized COVID-19 patients * Sustained anti-spike neutralization
Pharmacology
PMCID: PMC12171951 PMID: 40527546 DOI: 10.1136/bmj-2024-081336 Journal: BMJ (Clinical research ed.) Publication Date: 2025 Authors: Zeraatkar D, Nagraj SK, Ling M, Jassal T, Kirsh S, et al. Key Points * Patient education and pharmacist-led interventions showed the most promise in facilitating BSH discontinuation * Low-certainty evidence suggests 144 more patients
Immunology
PMCID: PMC12174348 PMID: 40527893 DOI: 10.1038/s41467-025-60628-1 Journal: Nature communications Publication Date: 2025-6-17 Authors: Kanno A, Kito T, Maeda M, Yamaki S, Amano Y, et al. Key Points * First monovalent antibody designed to specifically block pathogenic NMDAR autoantibodies without receptor dysfunction * Demonstrated 74% reversal of NMDAR internalization at 2.